Stoke Therapeutics insider executes 25,000-share exercise/sale at $30

Rhea-AI Filing Summary

Stoke Therapeutics director Edward M. Kaye reported transactions under a Rule 10b5-1 plan dated 12/30/2024. On 10/08/2025 he exercised a stock option with a $0.6 exercise price to acquire 25,000 shares and simultaneously sold 25,000 shares at $30 per share, leaving him with 49,124 shares beneficially owned. The option is fully vested; original vesting began on 10/17/2018 with monthly vesting thereafter, and the reporting was authorized by an attorney-in-fact on 10/10/2025. The filing indicates these actions were made pursuant to the 10b5-1 trading plan to satisfy the affirmative defense conditions.

Positive

• Use of a Rule 10b5-1 plan suggests trades were prearranged and intended to comply with insider-trading rules
• Option was fully vested, indicating no ongoing service condition for this exercised tranche

Negative

• Insider sold 25,000 shares, representing a reduction in personal holdings to 49,124 shares
• Sale price of $30 may reflect personal liquidity rather than confidence signal; transaction was executed

Insights

Corporate Insider Transactions Analyst

TL;DR: Director exercised fully vested options and sold an equal number of shares under a 10b5-1 plan.

The reporting person exercised a stock option at $0.6 per share and sold 25,000 shares at $30, which is a routine option-exercise-and-sell that left total beneficial ownership at 49,124 shares. The report cites a 12/30/2024 Rule 10b5-1 plan, which documents prearranged timing for the trades.

Dependencies and near-term items to watch include any future scheduled transactions under the same plan and changes in beneficial ownership reported in subsequent Form 4 filings; such updates would show additional dilution or insider liquidity events over the coming months.

Insider Trade Summary

Exercise and Sale: 25,000 shares ($735K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Kaye Edward M. MD

Role Director

Sold 25,000 shs ($750K)

Approx. gross sale proceeds $750K

Approx. exercise cost $15K

Approx. pre-tax spread $735K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	25,000	$0.00	$0.00
Exercise	Common Stock	25,000	$0.60	$15K
Sale	Common Stock	25,000	$30.00	$750K

Holdings After Transaction: Stock Option (Right to Buy) — 542,801 shares (Direct); Common Stock — 49,124 shares (Direct)

Footnotes (2)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
2. F2. The option vested as to 1/4th of the total award on October 17, 2018, with another 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Accordingly, this stock option is now fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/10/2025 - 04:12 PM Learn about SEC filing dates

FAQ

What did Stoke Therapeutics director Edward M. Kaye report on Form 4 (STOK)?

He reported exercising a stock option at $0.6 per share for 25,000 shares and simultaneously selling 25,000 shares at $30 on 10/08/2025, leaving 49,124 shares beneficially owned.

Were the trades linked to a 10b5-1 plan for STOK insider Edward Kaye?

Yes. The filing states the trades were effected pursuant to a Rule 10b5-1 trading plan adopted on 12/30/2024.

Is the stock option fully vested according to the Form 4?

Yes. The explanation says the option vested partially starting on 10/17/2018 with monthly vesting thereafter, and is now fully vested.

How many shares does Edward Kaye own after the reported transactions?

The Form 4 reports 49,124 shares beneficially owned following the transactions.

Who signed the Form 4 and when was it dated?

The Form is signed by an attorney-in-fact, Jonathan Allan, with a signature date of 10/10/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/08/2025		M(1)		25,000	A	$0.6	74,124	D
Common Stock	10/08/2025		S(1)		25,000	D	$30	49,124	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.6	10/08/2025		M(1)			25,000	(2)	04/02/2028	Common Stock	25,000	$0	542,801	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

2. The option vested as to 1/4th of the total award on October 17, 2018, with another 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Accordingly, this stock option is now fully vested.

	/s/ Jonathan Allan, Attorney-in-Fact	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.